Glucose sensor excludes hypoglycaemia as cause of death
Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.Diabetes research and clinical practice (Impact Factor: 2.54). 02/2012; 96(2):e30-2. DOI: 10.1016/j.diabres.2012.01.019
The cause of death can be difficult to verify post-mortem in unexpected deaths in patients with Type 1 diabetes. This report describes an unexpected death in a 44-year-old man with Type 1 diabetes treated with sensor-augmented pump therapy. Continuous glucose monitoring data proved useful in determining the cause of death.
- [Show abstract] [Hide abstract]
ABSTRACT: Background: This follow-up study investigates the metabolic and psychosocial effects of sensor-augmented pump (SAP) therapy in adults with type 1 diabetes 36 months after therapy start. Subjects and methods: We invited all 24 Danish adults with type 1 diabetes who had previously participated in the European multicenter randomized controlled Eurythmics Trial. Thirteen of the 24 patients started SAP therapy during the Eurythmics Trial; 11 patients were controls but started using SAP immediately after completion of the trial. In the current study, we estimated the effects of SAP 36 months after therapy start by change in glycated hemoglobin (HbA1c) and diabetes questionnaire scores (Diabetes Treatment Satisfactions Questionnaire [DTSQs], Problem Areas in Diabetes [PAID] questionnaire, and Hypoglycemia Fear Survey [HFS]). Results: At 36 months, 16 of the 24 patients were still using SAP, 14 of them > 70% of time. The HbA1c level decreased from 8.7% at therapy start to 7.3% at 36 months (P < 0.0001). Similar reductions in HbA1c were obtained regardless of whether SAP therapy was initiated during or after the Eurythmics Trial. DTSQs, PAID questionnaire, and HFS scores improved by 9.0 (P < 0.0001), -10.8 (P = 0.013), and -5.5 (P = 0.152), respectively, in the 16 SAP users. Conclusions: This study documents persisting beneficial effects of SAP on HbA1c, treatment satisfaction, magnitude of diabetes-related problems, and fear of hypoglycemia 36 months after therapy start. The follow-up is considerably longer than in other published studies; still, the results are in line with the positive short-term outcomes of larger studies of SAP use.Diabetes Technology & Therapeutics 09/2012; 14(12). DOI:10.1089/dia.2012.0148 · 2.11 Impact Factor
Article: Continuous glucose monitors[Show abstract] [Hide abstract]
ABSTRACT: Advances in diabetes technologies allow patients to manage their diabetes with greater precision and flexibility. Many recent studies show that continuous glucose monitors (CGMs) can be used to tighten glycemic control safely and to ease certain burdens of diabetes self-management. The following summary reflects the most recent findings in CGM and provides an overall review of who would most benefit from CGM use. Benefits of CGM may vary based on age, type of diabetes, pregnancy, health, sleep, or heart rate. Accuracy and reliability are critical in current uses of CGM and especially for new and future systems that automate insulin partially (e.g., low glucose suspend) or entirely (e.g., 'fully closed-loop' artificial pancreas). Clinicians are simultaneously testing available products in new patient groups such as the critically ill and type 2 diabetes patients not using mealtime insulin. In a widening set of circumstances, use of CGM has been shown to promote safer and more effective glycemic control than self-monitoring of blood glucose. Imperfections remain in certain scenarios such as hypoglycemia and in certain populations such as young children. Ongoing research on sensors and calibration software should translate to better systems.Current opinion in endocrinology, diabetes, and obesity 04/2013; 20(2):106-11. DOI:10.1097/MED.0b013e32835edb9d · 3.37 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.